C-type lectin domain family 4 member AGenealiases: CD367 · CLECSF6 · DCIR · DDB27 · HDCGC13P · LLIR
Q-omics provides the consensus-scored CLEC4A profile across patient tissues and cancer cell-line models. CLEC4A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, CLEC4A is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, CLEC4A protein abundance shows 20,879 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where CLEC4A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLEC4A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLEC4A survival associations across molecular data types. CLEC4A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLEC4A RNA expression–survival associations across cancer types. High CLEC4A expression shows unfavorable associations in UVM, but favorable associations in SKCM, HNSC, CESC, CHOL and LUAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for CLEC4A RNA expression.
This table summarizes CLEC4A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CLEC4A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLEC4A shows lower tumor expression in LUSC and LUAD and higher tumor expression in KIRC, THCA, HNSC and STAD. The KIRC box plot shows higher CLEC4A RNA expression in tumor versus normal tissue (log2 FC = +1.730, t-test p < 0.001).
This table shows molecular features associated with CLEC4A in patient tissues and cancer cell lines. In patient samples, CLEC4A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CLEC4A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
